Genentech Posts Solid Second Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
EPS misses consensus, but sales of most products modestly estimates.
You may also be interested in...
Avastin/Tarceva Combo Fails In Second-Line NSCLC
Industry analysts see little consequence, as each is already well-positioned in lung cancer.
Avastin/Tarceva Combo Fails In Second-Line NSCLC
Industry analysts see little consequence, as each is already well-positioned in lung cancer.
Retaane Fails Again In Macular Degeneration
Alcon halts program after large risk-reduction trial disappoints.